Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to find out if the plasma concentration of galantamine extended release is changed when BMS-708163 is administered at the same time.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Galantamine

Criteria

Inclusion Criteria:

• Healthy men and postmenopausal women

Exclusion Criteria:

• Gastrointestinal disorders

• Bleeding disorders

• Peptic ulcer disease

• Cholecystectomy

• Seizure disorder

• Asthma

• Chronic obstructive pulmonary disease

• Urinary tract obstruction

• Cardiac conduction abnormalities, including but not limited to "sick sinus syndrome" and those with unexplained syncopal episodes

• Inability to tolerate oral medication

• Inability to be venipunctured and/or tolerate venous access